By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
Health

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

GlobeNews Wire
Last updated: 08/06/2025 9:36 PM
GlobeNews Wire
Published: 08/06/2025
Share
SHARE

June 06, 2025 16:05 ET  | Source: PolyPid Ltd.

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call.

Conference Call Dial-In & Webcast Information:

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

Vodafone and Cyient unveil AI-Powered Network Configuration Management Solution to deliver Data driven, Smarter Network Operations
Countries Urged to Establish National Refrigeration Committees to Tackle Food, Health, Animals and Climate Challenges
Las Vegas News Briefs October 2024
Lulutox Tea UK (Lulutox Tea Detox) Officially Launches in Ireland, USA, Australia & Canada for Natural Digestive Cleanse
Acies TechWorks’ Kepler wins the 2025 ‘IFRS 9 Solution of the Year’
TAGGED:2025andcallconferenced-plexdiscusshostIL0011326795junemondayNasdaq:PYPDnewsphasepolypidresultsshieldtoplinetrialwebcast
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Odisha Chief Minister Mohan Charan Majhi Leads Groundbreaking Ceremony for Hygenco’s Landmark Green Ammonia Plant
News

Odisha Chief Minister Mohan Charan Majhi Leads Groundbreaking Ceremony for Hygenco’s Landmark Green Ammonia Plant

06/06/2025
Red Cat Holdings Announces Closing of $46.75 Million Registered Direct Offering of Common Stock
ATLAS SkillTech University Convocation 2025: 1088 Future-Ready Graduates Set to Thrive in Emerging Industries
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Hettich Showcases Future-Ready Furniture Innovations at Interzum 2025
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?